NATIONAL INSTITUTES OF HEALTH
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Phase 1
Completed
- Conditions
- Medullary Thyroid CarcinomaMultiple Endocrine Neoplasia Type 2AMultiple Endocrine Neoplasia Type 2B
- Interventions
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00514046
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the HypopharynxStage III Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the Larynx
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT00513435
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
Phase 3
Completed
- Conditions
- Stage IB Breast CancerStage II Breast CancerStage IIIA Breast CancerHER2/Neu PositiveStage IA Breast Cancer
- Interventions
- Other: Laboratory Biomarker AnalysisProcedure: Therapeutic Conventional SurgeryBiological: Trastuzumab
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 280
- Registration Number
- NCT00513292
- Locations
- πΊπΈ
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
πΊπΈEden Hospital Medical Center, Castro Valley, California, United States
πΊπΈMarin Cancer Care Inc, Greenbrae, California, United States
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Phase 2
Completed
- Conditions
- MelanomaMalignant MelanomaMelanoma, ExperimentalExperimental Melanomas
- Interventions
- Biological: aldesleukinBiological: therapeutic autologous lymphocytesRadiation: Total body irradiation
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 158
- Registration Number
- NCT00513604
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
Phase 1
Terminated
- Conditions
- Adenocarcinoma of the ProstateRecurrent Prostate Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00512668
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase 2
Completed
- Conditions
- Hormone-resistant Prostate CancerRecurrent Prostate Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT00513071
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
Phase 2
Terminated
- Conditions
- Skin CancerMelanoma
- Interventions
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2013-01-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00509496
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Phase 2
Completed
- Conditions
- MelanomaSkin Cancer
- Interventions
- Biological: autologous anti-MART-1 F5 T-cell receptorBiological: AldesleukinBiological: autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2012-12-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00509288
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Aflibercept in Treating Patients With Myelodysplastic Syndromes
Phase 2
Terminated
- Conditions
- de Novo Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableSecondary Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesAtypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Interventions
- Biological: ziv-afliberceptOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00509249
- Locations
- πΊπΈ
City of Hope Medical Center, Duarte, California, United States
Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Stage IV Breast CancerRecurrent Breast CancerBreast Cancer
- Interventions
- Procedure: pharmacological studyProcedure: laboratory biomarker analysis
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00509587
- Locations
- π¨π¦
BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
π¨π¦The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus, Ottawa, Ontario, Canada
π¨π¦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada